Human Papillomavirus (HPV)NCT07231263
Effect of HPV Education on Women's Knowledge
A study testing HPV Awareness Education Group in people with Human Papillomavirus (HPV) and Awareness and Knowledge Level, run by Kahramanmaras Sutcu Imam University at 1 site in Turkey (Türkiye).
Trial summary
This interventional study aims to evaluate the effectiveness of an educational program on women's knowledge of Human Papillomavirus (HPV), HPV vaccination, and screening. HPV is a major public health concern worldwide and a leading cause of cervical cancer. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Human Papillomavirus (HPV), Awareness and Knowledge Level
- What is being tested?
- HPV Awareness Education Group
- Type of treatment
- Vaccines
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 110 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 2 Oct 2025to 30 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- 18 years of age or older,
- Agreeing to participate in the study,
- Not experiencing communication difficulties,
- Female students who complete the data collection form in full will be included in the study.
Who cannot join
- Previously tested positive for HPV
- History of cervical cancer
- Unreachable
- Not attending public education during the training period
- Female students who did not complete the data collection form will be excluded from the study.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Kahramanmaraş Sütçü İmam Üniversitesi
Kahramanmaraş, onikişubat, 46000
About this study
Official title: The Effect of Human Papillomavirus Education Provided to Women on Their Level of Knowledge Regarding Human Papillomavirus
This interventional study aims to evaluate the effectiveness of an educational program on women's knowledge of Human Papillomavirus (HPV), HPV vaccination, and screening. HPV is a major public health concern worldwide and a leading cause of cervical cancer. Although cervical cancer is preventable through vaccination and early screening, HPV awareness among women remains limited in Türkiye. Educational interventions are therefore essential to improve knowledge and promote preventive health behaviors.
The study population consists of 110 women attending courses at the Suzan and Abdulhakim Bilgili Public Education Center in Onikişubat, Kahramanmaraş, Türkiye, between August 2025 and December 2025. No formal sample size calculation was performed. Instead, 80 women who met the inclusion criteria and voluntarily agreed to participate were included in the study.
Read more
Participants were randomly assigned to either the intervention group (education) or the control group (no education). The HPV education program is delivered in two 1-hour sessions using PowerPoint presentations and informational brochures developed from current literature and reviewed by experts in women's health nursing.
Data are collected before and after the educational sessions using a Personal Information Form and the HPV Knowledge Scale (HPV-KS), which measures participants' knowledge about HPV infection, vaccination, and screening. Statistical analyses will be conducted using SPSS 22.0, with descriptive statistics and inferential tests (paired-sample t-test, independent-sample t-test, repeated-measures ANOVA, and non-parametric equivalents) applied as appropriate. A p-value < 0.05 will be considered statistically significant.
It is hypothesized that women receiving HPV education will demonstrate significantly higher post-intervention knowledge scores compared to those in the control group.
Read the detailed description
Human papillomavirus (HPV) is a highly contagious virus that is recognized as a major public health problem both nationally and internationally due to its association with cervical cancer. Cervical cancer is a type of cancer within the category of gynecological cancers that can be detected early through screening programs, thereby preventing its progression. It ranks fourth among the most common cancers in women and remains a leading cause of cancer-related deaths. Globally, in 2020, there were 604,000 new cervical cancer cases and 342,000 deaths caused by cervical cancer. The World Health Organization recommends the inclusion of HPV vaccines in national immunization programs. While HPV vaccination rates are high in developed countries, there are delays in vaccine access in underdeveloped and developing countries . In Türkiye, HPV vaccination has not yet been incorporated into the national immunization program.
Cervical cancer remains one of the leading health concerns worldwide in terms of mortality and morbidity rates. The high incidence, insufficient HPV screening, and low awareness of HPV indicate the widespread presence of HPV infection . Increasing public awareness, preventing disease occurrence, and implementing protective planning and educational interventions are of great importance. One of the key strategies for addressing cervical cancer is to promote HPV screening .
In Türkiye, several studies have been conducted to assess the level of knowledge about HPV and its vaccine among healthcare personnel and students in health-related fields. The results of these studies have shown that participants' knowledge about HPV is not at the desired level . These studies revealed deficiencies in fundamental areas such as HPV-related infections, vaccination methods, and the effectiveness and importance of the vaccine. Such knowledge gaps may limit healthcare professionals' ability to provide effective health services and raise public awareness regarding HPV. Similarly, studies evaluating women's knowledge, attitudes, and behaviors about HPV and its vaccine have generally shown that women's knowledge of HPV is low
Therefore, HPV education is considered highly important. Educational programs can help participants make informed decisions and protect their sexual health. The findings obtained from such programs may guide the implementation of similar initiatives for larger communities and increase awareness about HPV. These kinds of studies play a crucial role in designing preventive measures and awareness-raising programs for public health, while also contributing to the limited existing literature. Accordingly, this study aims to examine the effect of HPV education provided to women on their level of knowledge regarding human papillomavirus.
- Being tested
- HPV Awareness Education Group
- Keywords
- Human papillomavirus (HPV), HPV education, Women's health;
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HPV Awareness Education GroupOther
Women who agree to participate in the training will receive a total of two hours of HPV awareness training in two sessions on the predetermined training date. The HPV awareness training will be delivered using a PowerPoint presentation, and at the end of the training, a brochure created in line with the literature will be distributed to the participating women to ensure retention. The brochure will be prepared by the researcher based on current literature sources. Expert opinions will be sought from specialists in the field of obstetrics and gynecology nursing regarding the training content, and revisions will be made if necessary. The training content will include the definition of HPV, risk factors, etiology, screening, HPV vaccination, transmission and prevention methods, and treatment. The training topics will be prepared by the faculty members responsible for the research in accordance with the literature.
| Study group | Role | What they receive |
|---|---|---|
| HPV Awareness Education Group | Experimental | Not described Receives: Other: HPV Awareness Education Group |
| Control Group | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
HPV knowledge level measured by the Human Papillomavirus Knowledge Scale (HPV-BÖ)
The Human Papillomavirus Knowledge Scale (HPV-KS) is a 33-item scale comprising four subscales: general HPV knowledge, HPV screening test knowledge, general HPV vaccine knowledge, and knowledge of the current HPV vaccination program. Items are answered as "Yes," "No," or "I don't know." Correct responses receive 1 point, whereas incorrect and "I don't know" responses receive 0 points. Total scores range from 0 to 33, with higher scores indicating greater HPV-related knowledge.
Measured: Baseline (pre-test) and immediately after the education session (post-test)
Secondary outcomes (4)
General HPV knowledge measured by the Human Papillomavirus Knowledge Scale (HPV-KS) - General HPV Knowledge Subscale
The General HPV Knowledge subscale of the Human Papillomavirus Knowledge Scale (HPV-KS) assesses participants' knowledge of HPV infection. Correct responses receive 1 point and incorrect or "I don't know" responses receive 0 points. Higher scores indicate greater knowledge of HPV infection
Measured: Baseline and immediately after the intervention
HPV screening test knowledge measured by the Human Papillomavirus Knowledge Scale (HPV-KS) - HPV Screening Test Knowledge Subscale
The HPV Screening Test Knowledge subscale assesses participants' knowledge of HPV screening tests. Correct responses receive 1 point and incorrect or "I don't know" responses receive 0 points. Higher scores indicate greater knowledge of HPV screening tests.
Measured: Baseline and immediately after the intervention
General HPV vaccine knowledge measured by the Human Papillomavirus Knowledge Scale (HPV-KS) - General HPV Vaccine Knowledge Subscale
The General HPV Vaccine Knowledge subscale assesses participants' knowledge of HPV vaccination. Correct responses receive 1 point and incorrect or "I don't know" responses receive 0 points. Higher scores indicate greater knowledge of HPV vaccination.
Measured: Baseline and immediately after the intervention
Knowledge of the current HPV vaccination program measured by the Human Papillomavirus Knowledge Scale (HPV-KS) - Current HPV Vaccination Program Knowledge Subscale
The Current HPV Vaccination Program Knowledge subscale assesses participants' knowledge of the current HPV vaccination program. Correct responses receive 1 point and incorrect or "I don't know" responses receive 0 points. Higher scores indicate greater knowledge of the current HPV vaccination program.
Measured: Baseline and immediately after the intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Nov 2025
- Study start2 Oct 2025
- Primary completion30 Nov 2025
- Study completion30 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Human Papillomavirus (HPV)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 110 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kahramanmaras Sutcu Imam University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fatma Keskin Töre, Kahramanmaras Sutcu Imam University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07231263
- Sponsor's protocol ID
- 2025/23/04
- Status last verified
- Jul 2026
- First submitted
- 13 Nov 2025
- Last updated
- 8 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
1. World Health Organization-WHO. Updates recommendations on HpV vacci- nation schedule
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Human Papillomavirus Education Provided to Women on Their Level of Knowledge Regarding Human Papillomavirus
- ClinicalTrials.gov ID
- NCT07231263
- Acronym / sponsor ID
- 2025/23/04
- Keywords
- Human papillomavirus (HPV), HPV education, Women's health;
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 110 participants (actual)
- Lead sponsor
- Kahramanmaras Sutcu Imam UniversityUniversity, hospital or other
- Study start
- 2 Oct 2025 (actual)
- Primary completion
- 30 Nov 2025 (actual)
- Study completion
- 30 Nov 2025 (actual)
- First posted
- 17 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This interventional study aims to evaluate the effectiveness of an educational program on women's knowledge of Human Papillomavirus (HPV), HPV vaccination, and screening. HPV is a major public health concern worldwide and a leading cause of cervical cancer. Although cervical cancer is preventable through vaccination and early screening, HPV awareness among women remains limited in Türkiye. Educational interventions are therefore essential to improve knowledge and promote preventive health behaviors.
The study population consists of 110 women attending courses at the Suzan and Abdulhakim Bilgili Public Education Center in Onikişubat, Kahramanmaraş, Türkiye, between August 2025 and December 2025. No formal sample size calculation was performed. Instead, 80 women who met the inclusion criteria and voluntarily agreed to participate were included in the study.
Participants were randomly assigned to either the intervention group (education) or the control group (no education). The HPV education program is delivered in two 1-hour sessions using PowerPoint presentations and informational brochures developed from current literature and reviewed by experts in women's health nursing.
Data are collected before and after the educational sessions using a Personal Information Form and the HPV Knowledge Scale (HPV-KS), which measures participants' knowledge about HPV infection, vaccination, and screening. Statistical analyses will be conducted using SPSS 22.0, with descriptive statistics and inferential tests (paired-sample t-test, independent-sample t-test, repeated-measures ANOVA, and non-parametric equivalents) applied as appropriate. A p-value < 0.05 will be considered statistically significant.
It is hypothesized that women receiving HPV education will demonstrate significantly higher post-intervention knowledge scores compared to those in the control group.
Detailed description
Human papillomavirus (HPV) is a highly contagious virus that is recognized as a major public health problem both nationally and internationally due to its association with cervical cancer. Cervical cancer is a type of cancer within the category of gynecological cancers that can be detected early through screening programs, thereby preventing its progression. It ranks fourth among the most common cancers in women and remains a leading cause of cancer-related deaths. Globally, in 2020, there were 604,000 new cervical cancer cases and 342,000 deaths caused by cervical cancer. The World Health Organization recommends the inclusion of HPV vaccines in national immunization programs. While HPV vaccination rates are high in developed countries, there are delays in vaccine access in underdeveloped and developing countries . In Türkiye, HPV vaccination has not yet been incorporated into the national immunization program.
Cervical cancer remains one of the leading health concerns worldwide in terms of mortality and morbidity rates. The high incidence, insufficient HPV screening, and low awareness of HPV indicate the widespread presence of HPV infection . Increasing public awareness, preventing disease occurrence, and implementing protective planning and educational interventions are of great importance. One of the key strategies for addressing cervical cancer is to promote HPV screening .
In Türkiye, several studies have been conducted to assess the level of knowledge about HPV and its vaccine among healthcare personnel and students in health-related fields. The results of these studies have shown that participants' knowledge about HPV is not at the desired level . These studies revealed deficiencies in fundamental areas such as HPV-related infections, vaccination methods, and the effectiveness and importance of the vaccine. Such knowledge gaps may limit healthcare professionals' ability to provide effective health services and raise public awareness regarding HPV. Similarly, studies evaluating women's knowledge, attitudes, and behaviors about HPV and its vaccine have generally shown that women's knowledge of HPV is low
Therefore, HPV education is considered highly important. Educational programs can help participants make informed decisions and protect their sexual health. The findings obtained from such programs may guide the implementation of similar initiatives for larger communities and increase awareness about HPV. These kinds of studies play a crucial role in designing preventive measures and awareness-raising programs for public health, while also contributing to the limited existing literature. Accordingly, this study aims to examine the effect of HPV education provided to women on their level of knowledge regarding human papillomavirus.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| HPV Awareness Education Group | Experimental | Other: HPV Awareness Education Group |
| Control Group | No intervention | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- 18 years of age or older,
- Agreeing to participate in the study,
- Not experiencing communication difficulties,
- Female students who complete the data collection form in full will be included in the study.
Key exclusion criteria (5 listed)
- Previously tested positive for HPV
- History of cervical cancer
- Unreachable
- Not attending public education during the training period
- Female students who did not complete the data collection form will be excluded from the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HPV Awareness Education GroupWomen who agree to participate in the training will receive a total of two hours of HPV awareness training in two sessions on the predetermined training date. The HPV awareness training will be delivered using a PowerPoint presentation, and at the end of the training, a brochure created in line with the literature will be distributed to the participating women to ensure retention. The brochure will be prepared by the researcher based on current literature sources. Expert opinions will be sought from specialists in the field of obstetrics and gynecology nursing regarding the training content, and revisions will be made if necessary. The training content will include the definition of HPV, risk factors, etiology, screening, HPV vaccination, transmission and prevention methods, and treatment. The training topics will be prepared by the faculty members responsible for the research in accordance with the literature. | Other | HPV Awareness Education Group |
Primary outcome
HPV knowledge level measured by the Human Papillomavirus Knowledge Scale (HPV-BÖ)
Time frame: Baseline (pre-test) and immediately after the education session (post-test)
The Human Papillomavirus Knowledge Scale (HPV-KS) is a 33-item scale comprising four subscales: general HPV knowledge, HPV screening test knowledge, general HPV vaccine knowledge, and knowledge of the current HPV vaccination program. Items are answered as "Yes," "No," or "I don't know." Correct responses receive 1 point, whereas incorrect and "I don't know" responses receive 0 points. Total scores range from 0 to 33, with higher scores indicating greater HPV-related knowledge.
4 secondary outcomes
General HPV knowledge measured by the Human Papillomavirus Knowledge Scale (HPV-KS) - General HPV Knowledge Subscale
Time frame: Baseline and immediately after the intervention
HPV screening test knowledge measured by the Human Papillomavirus Knowledge Scale (HPV-KS) - HPV Screening Test Knowledge Subscale
Time frame: Baseline and immediately after the intervention
General HPV vaccine knowledge measured by the Human Papillomavirus Knowledge Scale (HPV-KS) - General HPV Vaccine Knowledge Subscale
Time frame: Baseline and immediately after the intervention
Knowledge of the current HPV vaccination program measured by the Human Papillomavirus Knowledge Scale (HPV-KS) - Current HPV Vaccination Program Knowledge Subscale
Time frame: Baseline and immediately after the intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2026.
- Background1. World Health Organization-WHO. Updates recommendations on HpV vacci- nation schedule
- Individual participant dataSharing planned: Undecided
Related trials for Human Papillomavirus (HPV)
Not yet recruitingPhase 1/2
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human Papillomavirus Infection
Active, not recruitingPhase 4
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Immunization, HPV Infection
Not yet recruitingPhase 2
Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP)
Respiratory Recurrent Papillomatosis (RRP), Human Papillomavirus (HPV)
RecruitingPhase 2
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
RecruitingPhase 2
A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs at Minimal Risk and Primary Site Disease (SAVED)
Head and Neck Cancer, Head and Neck Squamous Cell Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing HPV Awareness Education Group in people with Human Papillomavirus (HPV) and Awareness and Knowledge Level, run by Kahramanmaras Sutcu Imam University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HPV knowledge level measured by the Human Papillomavirus Knowledge Scale (HPV-BÖ) (time frame: Baseline (pre-test) and immediately after the education session (post-test)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07231263, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026.